• search
  • menu
Swipe to the left

NEW Products | anti-GAD65 Radioimmunoassay (50 & 100 tests)

May 24, 2018

Mar 23, 2018 1:50:52 AMWe are pleased to announce the release of our anti-GAD65 RIA kit for the determination of autoantibodies to Glutamic Acid Decarboxylase (GAD65Ab) in human serum.

Type 1 diabetes, also known as insulin-dependent diabetes mellitus (IDDM), results from a chronic autoimmune destruction of the insulin-secreting pancreatic beta cells, probably initiated by exposure of genetically susceptible host to an environmental agent. Autoimmune destruction of beta cells is thought to be completely asymptomatic until 80-90% of the cells are lost. This process may take years to complete and may occur at any time in all ages.

During the preclinical phase, this autoimmune process is marked by circulating autoantibodies to beta cell antigens. These autoantibodies are present years before the onset of type 1 diabetes and prior to symptoms. Early studies utilized the immunofluorescence test for islet-cell antibodies (ICA), which has been difficult to standardize and is now replaced by a combination of several radioimmunoassays for antibodies against specific beta cell antigens, such is insulin (IAA), glutamic acid decarboxylase (GAD) and tyrosine phosphatase ICA 512 (IA2).

GAD, the enzyme that catalyzes the conversion of glutamate to GABA, has been identified in two isoforms, molecular weight 65.000 (GAD65) and 67.000 (GAD67). Although GAD autoantibodies are found in type 1 diabetes and in the rare neurological disorder Stiff man syndrome (SMS), the GAD autoantibodies profile in the two diseases differs. Autoantibodies of SMS samples recognize a combination of linear and conformational epitopes of GAD while GAD autoantibodies in samples with type 1 diabetes are predominantly directed to the conformational epitopes. GAD65 autoantibodies are present in 70-80 % of newly diagnosed samples with type 1 diabetes and can be detected many years before onset of the disease.

The combination of the autoantibodies to GAD65 and IA2 is highly relevant for risk assessment of type 1 diabetes in children and adolescence. These tests in combination are more sensitive and predictive than ICA in risk groups, e.g. relatives of type 1 diabetes. GAD65 autoantibodies also occur in a subset of adults with type 2 diabetes (non-insulin-dependent diabetes mellitus). These samples can have pronounced hyperglycemia, and after therapy with oral hypoglycemic agents for several months to years they may become insulin dependent. Therefore, these samples are thought to have a slowly progressive form of type 1 diabetes, sometimes called latent diabetes or latent autoimmune diabetes in adults (LADA). The presence of GAD65 autoantibodies in sera of such samples is a sensitive and specific marker for future insulin dependency.

The anti-GAD65 RIA kit is a direct assay based on the principle of radioligand assays. Highly purified human recombinant GAD65 is labeled with 125Iodine. This tracer is used in excess and bound by the GAD65 autoantibodies of the sample.

This test kit is offered in 50 test and 100 test formats. For research use only. Not for use in diagnostic procedures. View the product pages for more information and pricing:

#KIRM2070 anti-GAD65 RIA (100 tests)

#KIRM2017 anti-GAD RIA (50 tests)

Reliable Catecholamines ELISAs for Plasma and Urine Samples

May 16, 2018

Mar 23, 2018 1:50:52 AMEpinephrine (Adrenaline), Norepinephrine (Noradrenaline) together with Dopamine constitute the group of catecholamines, which play an important role as hormones and neurotransmitters. After they have exerted their effects, the catecholamines are broken down via intermediate products (Metanephrine, Normetanephrine, 3-Methoxytyramine respectively) and finally excreted in urine. Diseases which are associated with altered levels of catecholamines include hypertonia, degenerative heart diseases, and catecholamine-producing tumors (pheochromocytoma, neuroblastoma, ganglioneuroma). Of these, pheochromocytoma has the greatest significance. Around 10% of all pheochromocytomas show malignant growth and an unidentified pheochromocytoma poses a serious health risk to the individual. The determination of catecholamines is therefore essential in subjects with suspected pheochromocytoma.

This group of assays is intended for the measurement of the catecholamines Epinephrine (Adrenaline), Norepinephrine (Noradrenaline) and Dopamine in urine and/or plasma samples.

Principle of these assays: All three catecholamines are extracted in one run from the plasma or urine samples using an extraction plate which is coated with a cis-diolspecific affinity gel. After this very effective and efficient extraction procedure the catecholamines are modified and enzymatically converted into their corresponding N-Acyl-derivatives. For the quantification of these N-Acyl-derivatives ELISA methods are available.

COMMON FEATURES:

  • Speed and ease of use
  • For in-vitro diagnostic and research applications
  • Elegant and efficient extraction method
  • Excellent sensitivity and specificity
  • Wide standard ranges
  • The ELISA is automatable
  • Freedom from drug interferences
  • Excellent correlation with HPLC
  • Single and multi parameter kits available
ELISA – SINGLE PARAMETER KITS CATALOG

Adrenaline ELISA

IB89551

Noradrenaline ELISA

IB89552

Dopamine ELISA

IB89547
ELISA – MULTI PARAMETER KITS CATALOG

Adrenaline/Noradrenaline 2-CAT ELISA

IB89549

Adrenaline/Noradrenaline/Dopamine 3-CAT ELISA

IB89550


View our full selection of Biogenic Amines here.

Visit Us at the 2018 Digestive Disease Week

May 9, 2018

Visit our team at the 2018 DDW Digestive Disease Week!

Recognized as one of the top 50 medical meetings by HCEA, Digestive Disease Week® (DDW) is the world's largest gathering of physicians, researchers and industry in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

Saturday, June 2nd - Tuesday, June 5th

Walter E. Washington Convention Center, Booth #616

Washington D.C.

Contact us to set up a meeting!


We will be featuring our ELISA kits for the measurement of biologics related to IBD and other diseases. Their brand name is ImmunoGuide®. The product range is covering the following parameters:

Infliximab, Etanercept, Adalimumab, Golimumab, Tocilizumab, Vedolizumab and Certolizumab Pegol

For the monitoring of these mAb drugs we are supplying quantitative ELISA test kits measuring the free drug concentration by using as a catcher:
  • the target molecule (in most cases TNF-alpha)
  • a highly specific mAb directed against the drug
In addition we are supplying ELISA testkits for the semi-quantitative determination of anti-drug antibodies generated by immunogenicity specifically measuring:
  • the free anti-drug antibody concentration or alternatively
  • the total anti-drug antibody concentration

Please visit our booth to speak with our experts about our support for clinical studies and/or scientific projects in the development and application of biologics in medical research.

View our Research Drug Monitoring page.

March & April 2018 Publications

May 4, 2018

In March and April 2018, researchers worldwide cited IBL-America products in their publications. View the references below to see if we can partner with you in your upcoming research.

Association of cognitive function and liability to addiction with childhood herpesvirus infections: A prospective cohort study
MM Vanyukov, VL Nimgaonkar, L Kirisci… - Development and …, 2018 - cambridge.org
… manufacturer. IgG class antibodies to T. gondii, CMV, and EBV (viral capsid antigen)
were measured using solid phase immunoassay kits (IBL-America, http://www.
ibl-america.com) according to protocols provided by the manufacturer …

Usefulness of a single-assay chemiluminescence test (Tularaemia VIRCLIA IgG+ IgM monotest) for the diagnosis of human tularemia. Comparison of five serological …
Á Cubero, C Durántez, A Almaraz… - European Journal of …, 2018 - Springer
… April 2018 , Volume 37, Issue 4, pp 643–649 | Cite as. Usefulness of a single-assay
chemiluminescence test (Tularaemia VIRCLIA IgG + IgM monotest) for the diagnosis of human
tularemia. Comparison of five serological tests … Francisella tularensis IgG (ELISA). IBL America

Factors Associated with Lower Respiratory Tract Infections in HIV-Exposed Uninfected Infants
A Weinberg, MM Mussi-Pinhata, Q Yu… - AIDS research and …, 2018 - liebertpub.com
… These assays were performed by technologists blinded to the group allocation of the sample
using the following kits according to the manufacturer's instructions for quantitative assays:
Influenza A IgG ELISA (IBL America), respiratory syncytial virus (RSV) IgG ELISA (IBL

Leptin stimulates aromatase in the growth plate: limiting catch-up growth efficiency
M Masarwi, R Shamir, M Phillip… - Journal of …, 2018 - Soc Endocrinology
… Kit (cat. no. MOB00, R&D Systems); Mouse/Rat Testosterone ELISA kit (cat. no.
IB79174, Immuno-Biological Laboratories (IBL-America), Minneapolis, MN, USA).
Histological staining and measurement of growth plate height …

Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy
R Martinez, H Al-Jobori, AM Ali, J Adams… - Diabetes, 2018 - Am Diabetes Assoc
… Diabetes Diabetes Publish Ahead of Print, published online March 30, 2018 Page 2. 2 … method
(Analox Reagent Instruments, International Point of Care, Ontario, Canada), plasma insulin (IBL
America , Minneapolis, MN) and C-peptide (MP Biomedicals, Santa Ana, CA) with

Lower Sustained Diphtheria and Pertussis Antibody Concentrations in Inflammatory Bowel Disease Patients
F Caldera, S Saha, A Wald, CA Garmoe… - Digestive diseases and …, 2018 - Springer
… Received: 1 November 2017 / Accepted: 23 March 2018 © Springer Science+Business Media,
LLC, part of Springer Nature 2018 … antibody titers were measured using enzyme-linked
immunosorbent assay according to the manufacturer's protocol (IBL America, Minneapolis, MN …

Reduced immunity to measles in adults with major depressive disorder
BN Ford, RH Yolken, FB Dickerson… - Psychological …, 2018 - cambridge.org
… Indexed by Google, on 23 Mar 2018 at 05:20:27, subject to the Cambridge Core terms of use,
available at https … Seropositivity was determined for IgG antibodies against measles blind to
diagnosis using a commercially available solid phase immunoassay (IBL America, www.ibl

Association of cytomegalovirus and Epstein-Barr virus with cognitive functioning and risk of dementia in the general population: 11-year follow-up study M Torniainen-Holm, J Suvisaari, M Lindgren… - Brain, behavior, and …, 2018 - Elsevier … 2.4. CMV and EBV IgG level measurement. Plasma samples were available from 6250 (88%) participants. CMV and EBV IgG levels were analysed by solid-phase immunoassay using commercially available assay kits (IBL America) as described by Dickerson et al. (2003) …

Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy R Martinez, H Al-Jobori, AM Ali, J Adams… - Diabetes, 2018 - Am Diabetes Assoc… Diabetes Diabetes Publish Ahead of Print, published online March 30, 2018 Page 2. 2 … method (Analox Reagent Instruments, International Point of Care, Ontario, Canada), plasma insulin (IBL America , Minneapolis, MN) and C-peptide (MP Biomedicals, Santa Ana, CA) with …

Effects of in utero and lactational exposure to new generation green plasticizers on adult male rats: a comparative study with di (2-ethylhexyl) phthalate O Albert, TC Nardelli, C Lalancette, BF Hales… - Toxicological Sciences, 2018… Serum testosterone levels were assessed using enzyme-linked immunosorbent assay kits (IB79106; IBL America, Minneapolis, MN) according to the manufacturer's instructions (dynamic range: 0.083 to 16 …

Reasons to Analyze Complement

May 1, 2018

Complement is an essential part of the innate immunity and therefore disturbances of the complement system leads to infections, amplify diseases etc. The complement function testing also verifies the effect of certain treatments. Therefore it is important to analyze the functional activity of the system.

Three major reasons to study complement function:

1. Complement deficiencies are associated with infections and autoimmune diseases. Deficiencies of the classical pathway are often associated with SLE, glomerulonephritis and susceptibility to infections. Deficiencies of the alternative pathway often leads to Neisserial infections etc. An excellent way to screen for deficiencies is to study the function of the three pathways of the system. (Ref 1, 2, 3)

2. Activation of the complement system is part of active autoimmune diseases and therefore reflects ongoing disease processes. For example in SLE it is important to follow activity of disease since complement activation follows disease activity and can detect flares. (Ref 4, 5)

3. New therapies are aiming at stopping or increasing complement activity and therefore complement function is important to assess. An example is the anti-C5 monoclonal antibody therapy, where complement function testing verifies effect of the treatment. (Ref 6)

Complement System Alternative Pathway, Complement System MBL Pathway, Complement System Classical Pathway, Complement System Screen

Contact us to learn more

____________________________________

Page References

1. Seelen MA et al. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Meth 2005;296: 187-198.

2. Tudoran R & Kirschfink M. Modern complement analysis: indications, methods and outlook. J Lab Med 2012;36.

3. Mollnes TE et al. Complement analysis in the 21st century. Mol Immunol 2007;44: 3838-3849. Open source.

4. Harboe M et al. Advances in assay of complement function and activation. Adv Drug Deliv Rev 2011.

5. Ceribelli A et al. Complement Cascade in Systemic Lupus Erythematosus Analyses of the Three Activation Pathways. Ann. N.Y. Acad. Sci. 2009; 1173: 427–434.

6. Testa S. et al; Interval extension of maintenance Eculizumab treatment in patients with atypical haemolytical uremic syndrome. Poster B5, 4TH International conference HUS-MPGNTTP
and related disorders, 2013.